Cellosaurus logo
expasy logo

Cellosaurus FIB1-11 (CVCL_XA78)

[Text version]
Cell line name FIB1-11
Synonyms FIB 1-11
Accession CVCL_XA78
Resource Identification Initiative To cite this cell line use: FIB1-11 (RRID:CVCL_XA78)
Comments Group: Patented cell line.
Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2081.
Monoclonal antibody isotype: IgG1, kappa.
Monoclonal antibody target: UniProtKB; P02675; Human FGB.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy Parent: CVCL_3412 (P3X63Ag8U.1)
Children:
CVCL_XA90 (FT2-14)CVCL_XA91 (FU1-74)CVCL_XA92 (FU2-16)
Category Hybridoma
Publications

DOI=10.1038/nbt1189-1163
Kurokawa T., Iwasa S., Kakinuma A.
Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to fibrin and tissue plasminogen activator.
Biotechnology (N.Y.) 7:1163-1167(1989)

PubMed=2107601; DOI=10.1016/0049-3848(90)90382-M
Kurokawa T., Iwasa S., Kakinuma A.
Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
Thromb. Res. 47 Suppl. 10:83-89(1990)

PubMed=1796414; DOI=10.1055/s-0038-1646486
Kurokawa T., Iwasa S., Kakinuma A., Stassen J.-M., Lijnen H.R., Collen D.
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Thromb. Haemost. 66:684-693(1991)

Patent=US5496549
Yamazaki H., Tanoue K., Iwasa S., Kurokawa T.
Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis.
Patent number US5496549, 05-Mar-1996

Patent=US5506135
Iwasa S., Kurokawa T., Toyoda Y.
Hybrid monoclonal antibodies, their production and use.
Patent number US5506135, 09-Apr-1996

Cross-references
Cell line collections (Providers) JCRB; IFO50174 - Discontinued
Cell line databases/resources CCRID; 4201PAT-CCTCC00055
Encyclopedic resources Wikidata; Q93553951
Entry history
Entry creation06-Sep-2019
Last entry update21-Mar-2023
Version number5